Company intelligence / Profile preview
Marvel Biosciences Corp.
Calgary, Alberta, Canadamarvelbiotechnology.com ↗
- Ownership
- Public · MRVL
- Development stage
- Other
01
Overview
The company is developing MB-204, a novel fluorinated derivative of Istradefylline (an approved anti-Parkinson's drug). Recent preclinical studies for Rett syndrome showed promising results, with plans to engage with the FDA to discuss these findings. The company was also awarded a $300,000 Alberta Innovates AICE Validates grant to support preclinical validation of MB204 for Alzheimer's disease.
- Therapeutic areas
- GastroenterologyOncologyPsychiatryNeurology
- Modalities
- Small moleculessynthetic chemical derivatives
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
iBraiN InstituteFRAXA
04
Financials
- Market cap
- $117B
- Total revenue
- $8.2B
- Enterprise value
- $118.3B
Beyond the preview
Go deeper on Marvel Biosciences Corp..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Marvel Biosciences Corp..